Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

COPD [chronic obstructive pulmonary disease] Patients Diagnosed With Gastro Esophageal Reflux Disease Have Decreased Rates of COPD Exacerbations After Treatment With High Dose Proton Pump Inhibitor Therapy (Esomeprazole or Lansoprazole).

Next Previous
Search
Trial Profile

COPD [chronic obstructive pulmonary disease] Patients Diagnosed With Gastro Esophageal Reflux Disease Have Decreased Rates of COPD Exacerbations After Treatment With High Dose Proton Pump Inhibitor Therapy (Esomeprazole or Lansoprazole).

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 12 Jun 2013

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lansoprazole (Primary) ; Esomeprazole
  • Indications Gastro-oesophageal reflux
  • Focus Pharmacodynamics

    • Most Recent Events

    • 23 Jul 2012 Primary endpoint added as reported by ClinicalTrials.gov.
    • 23 Jul 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 22 Oct 2010 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top